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Adjuvant Therapy After Revascularisation
D 4.13.1
Introduction
Vascular and endovascular procedures suffer a risk of
failure, either early, intermediate, or late. Several fac-
tors affect this risk, and the incidence differs consider-
ably between various types of procedures. The main
causes of failure can be categorised as (1) early-tech-
nical flaws or low flow or increased thrombogenicity;
(2) intermediate (6-24 months)-intimal hyperplasia;
and (3) late-progression of atheromatous disease.
Regarding open vascular procedures, factors that
affect failure are the use of autogenous versus syn-
thetic vascular conduits, endarterectomy versus
bypass procedures, and the location of the procedure,
for example, an aortic procedure compared with a dis-
tal reconstruction. This also relates to differences in
the calibre of the recipient arteries, occlusive lesions in
the inflow or outflow vessels, and the capacity of the
collateral circulation.
Bypass patency also depends on the calibre and
length of graft to be used. Progression of disease and
risk factors such as smoking and blood lipids have a
major implication on patency. At one extreme, an aor-
tobifemoral graft with a perfect outflow carries at least
a 90% 'l-year patency, whereas the corresponding fig-
ure for a prosthetic femorodistal bypass with restrict-
ed run-off might be 30% or even less. Technical prob-
lems, encountered during surgery or caused by sur-
gery, also greatly influence the immediate outcome of
the procedure. The same kind of factors presumably
influence the outcome of endovascular procedures.
However, some of these procedures have only come
into use recently, which means that less knowledge
exists on the incidence and magnitude of the prob-
lems.
Current adjuvant pharmacological treatment aims
to reduce either early failures due to thrombosis, inter-
mediate graft occlusions due to intimal hyperplasia, or
further progression of atherosclerosis. Even though
vein grafts are at much less risk of developing occlu-
sions than synthetic grafts, it is reasonable to discuss
them together because most of the expected problems
are of the same kind, though not of the same magni-
tude. Various pharmacological agents are in use to
prevent thrombosis. The two most important cate-
gories are antiplatelet therapy and anticoagulation.
Recently also, prostanoids and nitric oxide have been
tried clinically. Although exerting antiplatelet effects,
these compounds are discussed separately from
antiplatelet therapy.
D 4.13.2
Antiplatelet Therapy
Acetylsalicylic acid
Acetylsalicylic acid (ASA) has been recommended on
its own merits for reducing thrombotic events in all
patients with PAD (see Recommendation 28, p S71).
This discussion focuses on the use of ASA to assist
the patency of revascularisation procedures.
Acetylsalicylic acid has been investigated in ran-
domised clinical trials, either alone or in combination
with dipyridamole. In a 1982 report, patients with
PTFE grafts for either above-knee or below-knee
femoropopliteal bypass procedures were randomised
to either placebo, ASA alone. or ASA plus dipyri-
damole, starting preoperatively,' For below-knee
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grafts, no difference was found between the groups,
whereas those patients on placebo undergoing an
above-knee reconstruction had a significantly worse
outcome than those receiving ASA or ASA plus dipyri-
damole. In combined series with autologous veins and
PTFE grafts, no patency differences were seen with
placebo versus ASA or ASA plus dipyridamole treat-
ment given postoperatively in two series.s-'
In a large series, 549patients, all with a femoropopliteal
autologous vein bypass, were randornised to treat-
ment with either ASA plus dipyridamole or placebo.'
Patients were followed-up for 3 years, and there were
no differences in patency rates recorded between the
groups. Conversely, the Antiplatelet Trialists in their
meta-analysis found that not only survival but also
graft patency could be improved using ASA.s
A theoretical explanation for an early benefit of ASA
is given in a study by Goldman et al,6 finding a lower
thrombogenicity index with ASA and dipyridamole
treatment using Illindium-labeled platelets. Based on
current knowledge, ASA is recommended for those
undergoing interventions. A Danish review recently
concluded that there is evidence for lifelong treatment
with ASA after infrainguinal vascular reconstructions?
The authors also recommended a rather high dose
(300-500 mg ASA daily).
Recommendation 96: Antiplatelets as adjuvant
pharmacotherapy after revascularisation
Antiplatelet therapy should be started preopera-
tively and continued as adjuvant pharmacotherapy
after an endovascular or surgical procedure. Unless
subsequently contraindicated, this should be
continued indefinitely. Caution should be used in
patients in whom use of anticoagulants is
proposed.
Ticlopidille
Ticlopidine, as a more recent antiplatelet drug, has
proved effective in preventing vascular complica-
tions." A reduced platelet uptake on aortobifemoral
grafts has been shown." A recently published prospec-
tive, randomised, multicentre study has shown that
ticlopidine compared with placebo after
femoropopliteal or femorotibial saphenous vein
bypass procedures in 143 patients increased both sur-
vival and 2-year patency of saphenous vein bypass
grafts in the legs. 1O Some of the side effects of ticlopi-
dine, such as thrombocytopenia," do not appear to be
present with newer ADP inhibitors such as clopido-
grel.J2
Eur J Vase Endovasc Surg Vol 19 Supplement A, June 2000
D 4.13.3
AnticoagUlants
The use of unfractionated heparin (UFH) during vascu-
lar surgery is a Widespread routine. Recently, it was
shown that low-molecular-weight heparin (LMWH) is
as effective an anticoagulant as UFH during infrain-
guinal bypass surgery.13 Conversely, UFH has been
used more selectively during the postoperative course.
The main reason might be a risk of postoperative bleed-
ing and a need for careful monitoring of coagulation
parameters. The development of LMWH has changed
this perspective considerably, and studies have pointed
at beneficial effects of LMWH in the postoperative
management of infrainguinal bypass.
A randomised controlled study comparing LMWH
with ASA and dipyridamolet- showed significantly bet-
ter patency in the LMWH group, but restricted to
patients with CLI. This study combined results
achieved with both synthetic grafts and vein grafts. It
has been suggested that the conclusions are less valid
because only one fourth of the grafts were vein; the
remaining were various synthetic materials, and all
patients received LMWH for the first week postopera-
tively, after which the randomised scheme started. In
another randomised controlled trial comparing LMWH
and unfractionated heparin, it was shown that LMWH
was superior and as safe as unfractionated heparin in
prevention of early graft thrombosis.IS
Oral coumarin seems to increase patient survival, but
controversies exist as to whether graft patency could be
influenced. In two studies from Austria, it has been
shown that graft patency is improved in patients with
saphenous vein grafts receiving oral anticoagulation.
Both primary graft patency and limb salvage were sig-
nificantly increased.w'? In the first of these two studies,
this effect was restricted to patients operated on for CLI.
In this study, 12% of patients randomised to coumarin
were withdrawn for bleeding complications. Contrary
to these findings, a Swedish study, including patients
receiving either vein grafts or synthetic grafts, did not
indicate any better outcome in patients receiving oral
anticoagulation during a 3-year follow-up.» The place
for coumarin as adjuvant therapy after revascularisa-
tion procedures remains to be determined (see Critical
Issue 30, p S170).
D 4.13.4
Other Drugs
Dextran
Dextran is able to reduce platelet uptake on graft
surfaces'? and was shown to be beneficial during fol-
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low-up of "difficult lower extremity revascularisa-
tions" utilising either veins or synthetic grafts." The
graft occlusion rate at 1 week was 20.5% in the con-
trol group and 6.9% (0% in vein grafts) in the dex-
tran 40 group. By the end of the trial, the overall
advantage of dextran 40 was statistically significant
at all times up to and including 1 month and in the
subgroup with umbilical vein or prosthetic grafts,
significant benefit lasted up to 32 months. However,
there was no advantage in vein graft bypasses unless
they were carried to crural arteries.v The latter has
been confirmed in a recent single-centre prospective
randomised trial.21
Dextran has been used extensively in Sweden, but
there are few published studies that compare dex-
tran with other forms of treatment. Recently, dextran
70 was compared with LMWH for distal vascular
reconstructions. New data indicate few differences,
except considerably more side effects with dextran.v
Although anaphylactic reactions have been mitigat-
ed by pretreatment with the hapten, other complica-
tions such as wound bleeding and vascular overload
are not uncommon unless a strict protocol is fol-
lowed and certain categorical exclusions observed
such as recent myocardial infarction, congestive
heart failure, and renal insufficiency, particularly in
patients with diabetes. On this basis, dextran 70 can-
not be recommended as a routine measure and
should only be used in those distal bypasses in
which there is a predictably high risk of early throm-
bosis (eg, non-autogenous reconstructions or crural
bypasses) and no contraindications.
Prosianoids
Prostanoids such as the prostacyclin analog iloprost
have antiplatelet effects but also have effects on
white cell aggregation and adhesion as well as on
vasoconstriction. Flow increases in vein grafts dur-
ing distal vascular reconstructions after iloprost
injection have been shown.P In a large European
multicentre study on patients with CLI comparing
iloprost and placebo in distal vascular reconstruc-
tions using either vein grafts or synthetic grafts, no
Significant improvement could be shown with
respect to the I-year patency." Whether this failure
could be attributed to the short time of drug admin-
istration, only during the day of surgery and 2 sub-
sequent days, is uncertain but may be a possibility.
Interestingly, synthetic grafts performed better dur-
ing the first month, when patients were treated with
iloprost.
Nitric oxide
In a small series, nitric oxide has been administered
during infrainguinal bypass surgery, resulting in an
augmented graft flow and inhibition of depleted plas-
ma antioxidants. Results on patency have not yet been
presented.25
D 4.13.5
New Approaches
Activation of the glycoprotein (GP)IIb/I1Ia on the
platelet surface is the final pathway of platelet aggre-
gation, regardless of the initiating stimulus. Inhibitors
of GPIIb /I1Ia receptors include monoclonal antibodies
and peptidic as well as nonpeptidic synthetic specific
receptor blockers. Abciximab exchanges between and
binds to platelets for as long as 2 weeks, whereas syn-
thetic GPIIb/I1Ia inhibitors block ex vivo platelet
aggregation only a few hours after the end of an infu-
sion but have the advantage of also being orally
active. New ways to interfere with the complex coag-
ulation system abound. Direct inhibitors of thrombin
is one of the recent pharmacological approaches being
evaluated in clinical trials. Other approaches are syn-
thetic inhibitors of factors VIII, IX or X, tissue factor
pathway inhibitors, or inactivated factor VIII.26,27,28
D 4.13.6
Adjuvant Therapy After Endovascular Procedures
For endovascular procedures, especially PTCA, anti-
coagulation has been advised, including oral anticoag-
ulation. However, in recent studies, the need for oral
anticoagulation has been questioned.t? Vascular stents
in the femoropopliteal region have been used without
long-term anticoagulation, and reasonably acceptable
early and intermediate patency rates have been
obtained.v although other authors have routinely
used coumarin.30,31,32.33.:>t,33 In a Swedish multicentre
study, patients were treated with ASA and dipyri-
damole or placebo after PTA of iliac and infrainguinal
vessels. No differences were recorded between the
groups with respect to the I-year patency rate.36
D 4.13.7
Summary of Adjuvant Therapy
Even though randomised controlled studies are not
entirely convincing, there seems to be consensus that
adjuvant pharmacotherapy is needed to prevent graft
thrombosis. Aspirin is the therapy most used, admin-
istered in a dose of 75 or 160 mg daily, although the
low-dose/high-dose debate is not settled. In most of
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the trials suggesting protected patency, the higher
dose of aspirin was used.I• 2.3 Conversely, compliance
may be a problem with the higher dose over time.
Whether LMWH should replace aspirin, for example,
for infrainguinal bypass, is not established. It seems
important to start the treatment preoperatively. It
seems reasonable to use the same policy for endovas-
cular procedures as for surgical procedures, and a reg-
imen with ASA is advised (see Recommendation 96, p
5210).
D 4.13.8
Intimal Hyperplasia
Proliferation of smooth muscle cells causing hyper-
plastic growth, especially in the distal anastomosis of
a synthetic graft or in the anastomoses or body of a
vein graft, is the main cause of graft failure during a
mid-term follow-up. Strict programs for graft surveil-
lance give an opportunity to treat the lesion before
any deleterious clinical effect, but most importantly,
measures to prevent this hyperplastic growth have to
be found. A major question is whether drugs that may
reduce thrombogenicity are usable for this purpose as
well. Drugs to be discussed are aspirin and heparin,
UFH or LMWH. Clinical effects of aspirin and dipyri-
damole were seen after peripheral vascular surgery;
however, with a short-term follow-up, this only
proves an effect on thrombus formation.F
Heparin (UFH) has been shown to inhibit prolifer-
ation and migration of smooth muscle cells even in
vivo.3S In animal models, an effect on intimal hyper-
plasia has been evident, however, any clinical benefit
in humans has not been proved.v It has been sug-
gested that a continuous heparin infusion has to be
used and also that LMWH has a greater effect on
native arteries than on vein grafts.40.4 1 Another pro-
posal is that very high doses of heparin are needed.P
The study reported above, intending to compare
aspirin and LMWH, claimed a beneficial effect of
LMWH on intimal hyperplasia.t! This conclusion is
not entirely evident, because the effect was seen
mostly in patients with severe ischaemia, in which
case an effect on thrombogenicity might be as impor-
tant as an effect on intimal hyperplasia. Several
experimental models have been tried to reduce inti-
mal hyperplasia. Some of them are listed in Table 55.
In addition, radiation and drug delivery from, or
together with, implanted stents are under evalua-
tion .43•44
Interestingly, almost all drugs reported in Table 55
exert a positive effect in the respective experimental
model. Whether any of these findings will be possible
to transfer to the human situation is too early to predict.
Apparently, cholesterol reduction is an interesting pos-
sibility, because it promises to reduce atherosclerosis,
but apparently also hyperplastic growth. Calcium
channel antagonists, lipid-lowering drugs, and treat-
ment of hypertension are all associated with reduced
progression of atherosclerosis, especially if combined
with smoking cessation and exercise. Whether this kind
of treatment will also affect intimal hyperplastic growth
has still to be proved. Both early thrombosis and late
hyperplastic growth are multifactorial events, and it
therefore would be most astonishing if one single drug
could prevent them all. Concerning the cells involved,
whitecells, and to a lesser degree, platelets, are crucial.
Maybe there is a future in drugs acting in different
ways to reduce platelet activity. Synergistic effects have
been shown with drugs acting on different pathways,
and a combination of cGMP- and cAMP-elevating and
cyclooxygenase-inhibiting drugs may be useful. Most
certainly, there will also be techniques to inhibit the
effects of activated white cells participating in the
inflammatory response.
Critical Issue 38: Agents to inhibit intimal hyper-
plasia
There is a need to determine the clinical efficacy of
agents reported to inhibit intimal hyperplasia in ani-
mal models. Because intimal hyperplasia is a major
cause of failure of both percutaneous and open sur-
gical revascularisation procedures, research aimed at
its prevention is of critical importance.
Table 55: Compounds used in animal model experimental settings to reduce intimal hyperplasia
Compound Experimental selling Effect
Naroparcil»
Sea vengers-s
L-arginine'7,....
Angiotensin-eonverting enzyme inhlbition-?
Cholesterol rcductionv
Ketanscrinu
FGF saporlnv
VEGP]
Cyclosporin>'
Lazaroidsv
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arterial injury
vein grafts
vein grafts
PTA
vein grafts
vein grafts
PTFEgrafts
vein grafts
aortic transplant
vein grafts
+
+
+
+
+
+
+
+
+
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Surveillance After Revascularisation
D 4.14.1
Introduction
Despite a high likelihood of immediate success, all
lower-extremity revascularisation procedures have a
significant rate of failure over time (see also B 4.4,
Surgery for Intermittent Claudication, p 597). It is
now well recognised that patency of the treated arteri-
al segment is most effectively preserved through sur-
veillance programs that are capable of identifying
flow-limiting lesions before complete occlusion of the
conduit or vessel. l ,2,3,4 Revision of failing reversed
saphenous vein bypass grafts, for example, results in
excellent long-term graft function, with assisted pri-
mary patencies of 82% to 92% at 5 years.w Once com-
plete occlusion has occurred, thrombectomy and revi-
sion yields a poorer secondary patency of only 43% to
76% at 5 years,7,s,9 Similarly, the treatment of complete
re-occlusions of angioplasty sites has a lower likeli-
hood of technical success, a higher incidence of com-
plications, and yields a less durable result. IO,1I
Clearly, the identification and treatment of flow-lim-
iting lesions within the treated arterial segment before
thrombosis of the segment provides a more durable
result. Surveillance programs, therefore, represent a
potentially valuable adjunct to every type of vascular
intervention performed for the preservation of lower
extremity perfusion. Because not all peripheral inter-
ventions are easily evaluated, the methods that pro-
vide the most cost-effective surveillance in a given set-
ting remain controversial.
D 4.14.2
Methods of Surveillance
A number of methods of posttreatment surveillance of
patients undergoing lower extremity revascularisation
have been practised over the past several decades.
These include clinical examination, ankle.brachial
indices, duplex imaging, and arteriography.
Additional study methods have been used, such as
segmental pressures and plethysmography, but little
information exists regarding the utility of these tech-
nologies.
Patient historyand clinical examination
Most patients (66%) who have undergone
femoropopliteal or femorotibial bypass procedures
experience a return of preoperative symptoms imme-
